Edition:
United States

Depomed Inc (DEPO.O)

DEPO.O on Nasdaq

7.69USD
11:01am EST
Change (% chg)

$0.30 (+4.06%)
Prev Close
$7.39
Open
$7.42
Day's High
$7.72
Day's Low
$7.34
Volume
204,348
Avg. Vol
1,472,640
52-wk High
$17.86
52-wk Low
$4.31

Chart for

About

Depomed, Inc. is a specialty pharmaceutical company. The Company focuses on pain and other central nervous system (CNS) conditions. Its products include NUCYNTA ER (tapentadol extended release tablets), NUCYNTA IR (NUCYNTA) (tapentadol), Gralise (gabapentin), CAMBIA (diclofenac potassium for oral solution), Zipsor (diclofenac... (more)

Overall

Beta: 1.04
Market Cap(Mil.): $465.67
Shares Outstanding(Mil.): 63.01
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 32.23 16.73
EPS (TTM): -- -- --
ROI: -- 14.02 35.60
ROE: -- 15.49 17.23

BRIEF-Depomed Announces Nucynta® Commercialization Agreement With Collegium Pharmaceutical

* DEPOMED ANNOUNCES NUCYNTA® COMMERCIALIZATION AGREEMENT WITH COLLEGIUM PHARMACEUTICAL

Dec 04 2017

BRIEF-Collegium To License Rights To Commercialize Nucynta Franchise

* COLLEGIUM TO LICENSE RIGHTS TO COMMERCIALIZE NUCYNTA FRANCHISE

Dec 04 2017

BRIEF-Depomed announces Q3 loss of $0.25 per share

* Depomed inc sees ‍2017 non-gaap total revenue $380 to $385 million​

Nov 07 2017

BRIEF-Depomed and Slán Medicinal Holdings announce strategic asset transactions

* Depomed and Slán Medicinal Holdings Ltd announce strategic asset transactions

Nov 07 2017

BRIEF-PDL Biopharma announces settlement agreement with Valeant

* PDL Biopharma - ‍Valeant to pay a one-time, lump-sum payment of $13.0 million as part of settlement

Oct 30 2017

BRIEF-Depomed ‍provides information on impact of hurricane Maria to supply of NUCYNTA ER​

* Says ‍provides information on impact of hurricane Maria to supply of NUCYNTA ER​

Oct 10 2017

Earnings vs. Estimates